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ABSTRACT
Recent cumulative evidence suggests the possibility of predict-
ing the in vivo metabolic clearance and/or hepatic availability
(Fh) from in vitro metabolism data under linear conditions. Un-
der nonlinear conditions, however, it is essential to consider the
rate constant for the absorption (ka) for predicting Fh after oral
administration, because the time profiles for the portal vein
concentration depends on ka. In our study, we numerically
solved the dispersion model under nonlinear conditions to pro-
pose a method to predict Fh after oral administration by taking
ka into consideration. As a model compound, (S)-(-)-2,8-di-
methyl-3-methylene-1-oxa-8-azaspiro [4,5] decane-L-tartrate
monohydrate (YM796) was used. After oral administration, we
found that the dose-normalized AUC (AUCoral/dose) was mark-
edly increased in rats from 5.031026 to 3331026 hr/mlzkg as
the dose increased from 1 to 10 mg/kg, whereas the same
value was relatively constant in dogs (87.731026 to 10531026
hr/mlzkg at 1 to 10 mg/kg) and in humans (126031026 to
176831026 hr/mlzkg at 5 to 60 mg/body). Kinetic analysis in-
dicated that AUCoral could be accurately predicted at each
dose if ka value was assumed as 0.07 min
21 for all animal
species examined in our study. These results suggest that it is
possible to predict Fh even if the metabolism is composed of
non-linear process by considering the absorption rate into the
portal vein.
It is important to predict hepatic metabolic clearance in
humans because many drugs are eliminated from the body by
metabolism in the liver. Rane et al. (1977) and Wilkinson
(1987) introduced the approach to predict the in vivo meta-
bolic clearance of drugs in rats from in vitro metabolism data
obtained by using rat liver microsomes and/or hepatocytes
based on pharmacokinetic models in which physiological and
biochemical parameters such as Qh and fb are considered. In
addition, it has already been reported that the aforemen-
tioned approach is suitable for many compounds metabolized
by cytochrome P-450 (Sugiyama et al., 1988; Houston, 1994).
We previously reported that this approach can be applied not
only to rats but also to dogs and humans under linear con-
ditions using (S)-(-)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro
[4,5] decane-L-tartrate monohydrate (YM796) which is being
developed as a drug to treat dementia (Iwatsubo et al., 1997c).
Some drugs such as propranolol exhibit nonlinear kinetics
in vivo in humans even at therapeutic doses (Ludden, 1991).
It is therefore important to establish a method with which
the nonlinear metabolism of drugs can be predicted based on
the in vitro data. The quantitative prediction of nonlinear
hepatic metabolism is complicated, particularly for orally
administered drugs, because the time profiles for the drug
concentration in the portal vein varies as a function of ka. In
our study, we propose a method to predict the nonlinear
hepatic availability of orally administered drugs from the in
vitro metabolism data; based on a dispersion model, which is
superior to well-stirred or parallel tube models for the pre-
diction of Fh for compounds with high extraction ratio (Iwat-
subo et al., 1997a). We could successfully predict the nonlin-
earity in the oral bioavailability by considering the ka and
metabolic parameters. As a model compound, we used
YM796, because the kinetic parameters for the hepatic mi-
crosomal metabolism have been determined in vitro in rats,
dogs and humans. In our study, AUCoral values of YM796 in
these animal species were predicted based on the in vitroReceived for publication April 15, 1997.
ABBREVIATIONS: AUCoral, area under the plasma concentration-time curve after oral administration; CLh, hepatic clearance; Clint, overall intrinsic
metabolic clearance (intrinsic hepatic clearance); CLns, intrinsic metabolic clearance for the nonsaturable component; CLoral, oral clearance (5
dose/AUCoral); CLr, renal clearance; DN, dispersion number; Fa, fraction absorbed from the intestinal tract; Fg, gastrointestinal availability; Fh,
hepatic availability; fb, unbound fraction in blood; fp, unbound fraction in plasma; GE, gastric emptying; Km,i, Michaelis-Menten constant for the
i-th component of the metabolic reaction; Qh, hepatic blood flow rate; RB, blood-to-plasma concentration ratio; Vmax,i, maximum metabolic rate
for the i-th component of the metabolic reaction.
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data and compared with those obtained in vivo to examine
the predictability under nonlinear conditions.
Materials and Methods
Chemicals and reagents. YM796 was synthesized in Yamanou-
chi Pharmaceutical Co., Ltd (Tokyo, Japan). Other reagents of ana-
lytical grade were purchased from Wako Pure Chemical Industries,
Ltd (Osaka, Japan).
Plasma concentrations of YM796 in rats, dogs and humans.
The doses used in the present study were 3.0 and 10.0 mg/kg for rats
and dogs (n 5 3), and 10, 20, 40 and 60 mg/subject for humans (n 5
5 or 6). For human studies, healthy male volunteers were recruited
and the study was carried out in the Kitasato University School of
Medicine. The protocol had been approved by the Institutional Re-
view Board of the university and written consent had been obtained
from each subject prior to the study. Plasma concentration of YM796
in each species was determined according to the method reported
previously (Iwatsubo et al., 1997c). At specified times after admin-
istration, blood specimens were collected. After centrifugation,
plasma was separated and stored at -20°C until analysis. YM796 was
extracted from plasma by liquid-liquid extraction and injected into a
gas chromatography tandem mass spectrometry system (Iwatsubo et
al., 1997c). The AUC values were calculated from the plasma con-
centration-time curves by the trapezoidal rule.
Prediction of dose-dependence in the bioavailability (F) or
AUCoral of YM796 in rats, dogs and humans from in vitro
metabolic data. A simulation was carried out based on the disper-
sion model to predict the dose-dependent Fh using the kinetic pa-
rameters previously obtained from in vitro studies (Iwatsubo et al.,
1997b, c). For the hepatic metabolism of YM796, a single saturable
component was assumed for rats, although two saturable compo-
nents and a single nonsaturable component were postulated for dogs
and humans. The nonlinear dispersion model, therefore, can be given
by equation (1) for rats and equation (2) for dogs and humans.
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where D represents the axial dispersion coefficient which characterizes
the degree of mixing or axial dispersion of a drug entering the portal
vein, z represents the axial coordinate in the liver, C represents the
concentration of solute at a distance z from the inlet to the liver, VB
represents the volume of blood space in the liver, Vh represents the
apparent volume of distribution in the liver, v represents the linear
velocity of blood in the liver (5 Qh/A 5 QhL/VB), Qh represents the
hepatic blood flow rate, A represents the vertical area of the hepatic
sinusoid, L represents the length from the inlet to the outlet of the liver,
fp represents the unbound fraction of YM796 in plasma and RB repre-
sents the blood-to-plasma concentration ratio of YM796. Equations (1)
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where CN 5 C/(dose/Vh), T 5 t/(Vh/Qh), Z 5 z/L, DN 5 D/(vL) 5
D/(LQh/A), KmN 5 Km/(dose/Vh), VmaxN 5 Vmax/(Qhzdose/Vh) and
CLnsN 5 CLns/Qh. The initial and boundary conditions are given by
equation (5).
at T 5 0: CN 5 0
at Z 5 0: CN2DN ­ CN/­ Z 5 kaN z e
2kaNzT (5)
at Z 5 1: ­ CN/­ Z 5 0
where kaN 5 ka/(Qh/Vh) and ka represents the first-order absorption
rate constant after oral administration. The Km and Vmax values for
rats were 13.4 mM and 520 nmol/min/g liver. The Km1, Km2, Vmax1,
Vmax2 and CLns values were 8.1 mM, 890 mM, 10.9 nmol/min/g liver,
570 nmol/min/g liver and 0.65 ml/min/g liver, respectively, for dogs,
and 1.7 mM, 650 mM, 1.3 nmol/min/g liver, 79 nmol/min/g liver and
0.06 ml/min/g liver, respectively, for humans (Iwatsubo et al., 1997b,
c). The fp and RB values were 0.694 and 1.10 for rats, 0.707 and 1.07
for dogs, and 0.700 and 1.11 for humans, respectively (Iwatsubo et
al., 1997c). A Qh value of 0.95 ml/min/g liver (Bischoff et al., 1971;
Dedrick et al., 1973; Montandon et al., 1975) and a DN of 0.17
(Roberts and Rowland, 1986; Iwatsubo et al., 1997b, c) were used.
The Vh value was estimated to be 1.5 ml/g liver based on the fp and
RB mentioned above and the unbound fraction of YM796 in the tissue
(fT 5 0.41) obtained using isolated rat hepatocytes (Vh 5 fp/RB/fT). In
the calculation of outflow concentrations of YM796 from the liver,
rapid equilibrium of the drug between blood and hepatocytes and the
absence of any active transport of the drug through the sinusoidal
membrane were assumed so that the unbound concentrations of the
drug in the liver were equal to those in blood at any point throughout
the liver. By solving partial differential equation (3) or (4) numeri-
cally with the Napp based on the finite difference method (Hisaka et
al., 1994), the time profile of unchanged drug concentrations (C) at a
distance of z from the inlet of the liver was obtained. The drug
concentrations at the outlet from the liver (hepatic vein) were inte-
grated from time zero to infinity to obtain the AUC. Then, the
calculated AUC was multiplied by the Qh to obtain the total amount
of unchanged drug that entered the circulating blood. Finally, the Fh
was calculated by dividing the aforementioned amounts by the dose.
For the calculation of AUCoral, the following calculations were
performed. Because the concentrations of YM796 in the circulating
blood is much lower than the Km value, we assumed that the metab-
olism of the drug after entering the circulating blood is linear. The
CLh under linear conditions can be calculated from the CLint ob-
tained from in vitro experiments based on equations (6);(9).
CLh 5 Qh~1 2 F9h! (6)
F9h 5 4a/@~1 1 a!
2exp$~a 2 1!/ 2DN%
2 ~1 2 a!2exp$ 2 ~a 1 1!/ 2DN%# (7)
where a 5 ~1 1 4RN z DN!
1/ 2 (8)
in which RN 5 ~fp/RB! z CLint/Qh (9)
Based on the in vitro experiments with liver microsomes,
CLint under linear conditions can be calculated from equation
(10) for rats and from equation (11) for dogs and humans.
CLint 5 Vmax/Km (10)
CLint 5 Vmax,1/Km,11Vmax,2/Km,21CLns (11)
Then, using CLr calculated from the urinary excretion for
unchanged YM796 (rat and dog: negligible, human: 1.0 ml/
min/kg), the CLh under linear conditions shown above and Fh
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calculated as a function of dose, the CLoral at each dose can be
calculated from equation (12).
CLoral 5 ~CLh 1 CLr!/F (12)
where F 5 Fa z Fg z Fh (13)
FazFg was assumed to be 0.88 for calculations in all species, because
the fraction of unchanged YM796 absorbed from the intestinal tract
was estimated as 88% by considering the difference in plasma con-
centrations between circulating arterial blood and portal vein blood
after administration of YM796 into the rat intestinal loop (Iwatsubo
et al., 1997c). Finally, the AUCoral was calculated from equation (14).
AUCoral 5 Dose/CLoral/RB
Effects of the absorption rate of YM796 on bioavailability
(F) in rats. The apparent absorption rate after oral administration
of a drug is considered to be rate-determined by GE when its absorp-
tion through the intestinal membrane is rapid, unless it is absorbed
directly from the stomach. The GE process is known to be described
by the first-order kinetics and its rate constant has been reported to
be approximately 0.1 min21 for humans (Oberle et al., 1990). Based
on these considerations, F values were simulated by the aforemen-
tioned method as a function of ka with the maximum value of 0.1
min21.
Results
Plasma concentrations of YM796 in rats, dogs and
humans. All parameters obtained from the plasma concen-
tration-time profiles after oral doses of YM796 in rats, dogs
and humans are summarized in table 1. The previously re-
ported parameters at the lowest dose for rats, dogs and
humans (Iwatsubo et al., 1997b, c) are also shown in table 1
for comparison. Plasma concentrations of the unchanged
drug reached a maximum at 0.50, 0.50 and 0.08 hr after oral
administration of YM796 at doses of 1, 3 and 10 mg/kg,
respectively in rats (fig. 1). In dogs and humans, the Tmax
values were slightly greater being .5;1.3 hr and 1.2;2.0 hr,
respectively (figs. 1 and 2). Both Cmax and AUCoral were
increased almost in proportion to the dose indicating linear
pharmacokinetics both in dogs and humans (figs. 1 and 2).
The AUCoral normalized by the dose (AUCoral/dose) remained
almost constant at 87.7;10531026 hr/mlzkg in dogs and
1260;176831026 hr/mlzkg in humans, respectively, al-
though in rats, the AUCoral/dose was increased markedly
from 5.031026 to 3331026 hr/mlzkg as the dose increased
(fig. 3). Similarly, a marked increase in F from 3.4 to 22.3%
was also observed in rats when the dose was increased,
whereas F remained almost constant at 16.1319.0% irre-
spective of dose in dogs (fig. 3).
Effects of the absorption rate of YM796 on bioavail-
ability (F) in rats. The F values of YM796 at each dose,
simulated using the previously obtained in vitro metabolism
parameters for rats, are shown in figure 4. The F value at a
high dose (10 mg/kg) was markedly affected by a change in ka
from 0 to 0.1 min21 and was found to be 3.2;28.4%, although
no pronounced change in F was observed at low doses (1 and
3 mg/kg) if the ka was changed. When ka was 0.1 min
21 (the
maximum value), the predicted F values at the dose of 1, 3
and 10 mg/kg were estimated to be 5.0, 7.7 and 28.4%, re-
spectively. With a ka of 0.07 min
21, the predicted values of F
were 4.8, 6.3 and 23.4%, comparable with those obtained in
vivo (3.4, 5.0 and 22.3%) at each dose.
Prediction of dose-dependence in the bioavailability
(F) or AUCoral of YM796 in rats, dogs and humans from
in vitro metabolic data. Because the predicted F values
Fig. 1. Plasma concentration time profiles of YM796
after oral administration in rats and dogs. Each
point represents the mean 6 S.D. of three animals.
F: 1 mg/kg; f: 3 mg/kg and Œ: 10 mg/kg.
TABLE 1









Rat 3 1.0a 5.0 3330 9.3 3.4
3 3.0 22.2 2252 33.9 5.0
3 10.0 333 501 819.0 22.3
Dog 3 1.0a 87.7 (17.0) 205 (39) 39.3 (7.1) 16.1 (2.5)
3 3.0 316 (104) 158 (47) 129 (34) 19.0 (5.1)
3 10.0 1041 (320) 160 (46) 559 (135) 18.7 (4.3)
Humanc 6 5.0b 117 (16) 11.1 (1.3) 19.8 (2.1)
6 10.0 180 (32) 13.2 (1.2) 35.3 (4.3)
6 20.0 408 (44) 11.7 (0.8) 68.1 (5.3)
6 40.0 1010 (132) 9.4 (1.3) 151 (10)
5 60.0 1482 (166) 9.6 (1.1) 266 (11)
Numbers in parentheses represent the standard errors of the mean values.
a The data were taken from Iwatsubo et al., 1997c.
b The data were taken from Iwatsubo et al., 1997b.
c The dose was given as mg/body for humans different from rats and dogs.
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were most similar to those in vivo if ka was 0.07 min
21 in
rats, prediction of the dose-dependence of F and AUCoral in
all animal species was attempted by using the metabolism
parameters (Km, Vmax) obtained from the in vitro studies and
a ka value of 0.07 min
21. The predicted AUCoral values after
oral administration of 1, 3 and 10 mg/kg YM796 to rats and
dogs were 5.5, 31.1 and 412, and 94.2, 323 and 1143 ngzhr/ml,
respectively, which were comparable with the in vivo values
in both animal species (5.0, 22.2 and 333, and 87.7, 316 and
1041 ngzhr/ml for rats and dogs, respectively) (fig. 5). Simi-
larly, the predicted values of AUCoral in humans (130, 201,
532, 1539 and 2197 ngzhr/ml) were also comparable with
those observed in vivo (117, 180, 408, 1010 and 1482 ngzhr/
ml) after oral administration of YM796 at doses of 5, 10, 20,
40 and 60 mg/subject, respectively, although the AUCoral
values at higher doses were overestimated to some extent
(fig. 5). In addition, the F values in rats and dogs at each dose
from in vitro metabolism data were successfully predicted.
The predicted F in humans was 71.7;81.0% which was
larger than that in rats and dogs and was not as markedly
affected by dose.
Discussion
As shown in figure 3, AUCoral of YM796 normalized by the
dose (AUCoral/dose) was found to be almost constant irrespec-
tive of the dose in dogs and humans, whereas in rats it
increased markedly from 5.031026 to 3331026 hr/mlzkg as
the dose increased. As a consequence, F in rats was deter-
mined as low as 3.4% at the low dose and increased markedly
as the dose increased, whereas F in dogs was also almost
constant (16;19%) independent of dose. F is given as the
product of 1) Fa, 2) Fg and 3) Fh. Considering the facts that
approximately 92% of the radioactive dose was recovered in
urine and bile after oral administration of 14C-YM796 (0.5
mg/kg) to rats and that the fraction of unchanged YM796
absorbed from the intestinal tract after administration of 1
mg/kg of YM796 into the rat intestinal loop was 88% (Iwat-
subo et al., 1997c), the marked first-pass metabolism in the
liver [factor 3)] should be the predominant factor to account
for the low F in rats at a low dose, and the nonlinearity in F
may be ascribed to saturation of first-pass metabolism in
liver.
Furthermore, figure 4 shows that F at a high dose (10
mg/kg) was markedly changed (3.2;28.4%) by the increase in
ka, whereas no pronounced change in F was observed at low
doses (1 and 3 mg/kg) by changing ka values. These results
may be accounted for by considering that the unbound
YM796 concentrations in the portal vein become greater than
the Km value as ka increases at the dose of 10 mg/kg, whereas
at the 1 and 3 mg/kg doses, they are less than Km even when
ka is 0.1 min
21. Indeed, the maximum concentrations of
unbound YM796 in the portal vein were estimated by com-
Fig. 2. Plasma concentration time profiles of YM796 after oral admin-
istration in humans. Each point represents the mean 6 S.D. of five or six
subjects. F: 5 mg/body; Œ: 10 mg/body; M: 20 mg/body; E: 40 mg/body and
‚: 60 mg/body.
Fig. 3. Dose-dependence of observed bio-
availability (A) and AUCoral/dose of YM796
in rats, dogs and humans. Each point rep-
resents the mean 6 S.D. of three animals
for rats and dogs and 5;6 subjects for hu-
mans. F: bioavailability or AUCoral/dose in
rats; Œ: bioavailability or AUCoral/dose in
dogs and f: AUCoral/dose in humans.
Fig. 4. Effects of the absorption rate on bioavailability of YM796 in rats.
The solid lines are the simulation curves of in vivo bioavailability after
oral dose at 1, 3 and 10 mg/kg of YM796 calculated from the parameters
obtained in vitro based on the dispersion model assuming the first-order
absorption. In the calculation, a dispersion number (DN) of 0.17, the
unbound fraction of YM796 in plasma (fp) of 0.7 and the hepatic blood flow
(Qh) of 0.95 ml/min/g liver were used.
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puter simulation [equations (3) and (5)] to be 3.8, 11.4 and
38.0 mM at the doses of 1, 3 and 10 mg/kg, respectively, when
ka was 0.1 min
21.
The F values of YM796 in humans predicted from the in
vitro metabolism data were as high as 72;81%, and no
marked nonlinearity in AUCoral was predicted at doses of 5 to
60 mg/man. Indeed, no nonlinearity in F and/or oral clear-
ance (dose/AUCoral) was observed in humans in vivo (figs. 3
and 5; table 1), although the Km value for the high-affinity
component estimated previously from the in vitro studies
with liver microsomes was lowest in humans (rat: 13.4 mM,
dog: 8.1 mM, human: 1.7 mM) and the maximum concentra-
tion of unbound YM796 in the portal vein was estimated to be
4.1 mM at the highest dose (60 mg/man) when ka was as-
sumed to be 0.07 min21. For this reason, the following pos-
sibilities can be considered.
1)The maximum plasma unbound concentrations of
YM796 in circulating blood at the highest dose in rats, dogs
and humans were calculated to be 568, 395 and 186 ng/ml
(1.6, 1.1 and 0.53 mM), respectively, taking into account the
unbound fraction in the plasma of each species (0.694, 0.707,
0.700). Because these values were lower than the Km values
for the high-affinity component in each species (13.4, 8.1 and
1.7 mM, respectively, Iwatsubo et al., 1997b, c), the elimina-
tion of YM796 entering the circulating blood, after the first-
pass through the liver after oral administration, can be as-
sumed to be linear.
2)Because the Vmax of the high-affinity component for hu-
mans was approximately 1/450 that of rats and 1/9 that of
dogs, the hepatic intrinsic clearance (Vmax/Km) was also the
lowest among the species studied. Therefore, the predicted F
value for humans was close to unity (0.72;0.81) so that the
hepatic availability was not considered to change very much
even when saturation of the first-pass metabolism in liver
occurs. For these reasons, no pronounced nonlinearity in the
oral clearance should have been observed in humans despite
the low Km value.
For dogs, the maximum concentration of unbound YM796
in the portal vein was estimated to be 34.7 mM at the highest
dose (10 mg/kg) when ka was 0.07 min
21. This value was
greater than the Km value for the high-affinity component
but much less than that for the low-affinity one. At this
concentration, the intrinsic metabolic clearances for the
high-affinity component, low-affinity component and nonsat-
urable component were 0.255, 0.616 and 0.650 ml/min/g liver,
and the latter two components primarily contributed to the
metabolism of YM796. This may be why no nonlinearity in F
and/or oral clearance (dose/AUCoral) was also observed in
dogs (figs. 3 and 5; table 1).
In this way, the method for prediction used in our study
seems useful to guide the development of a new drug in its
preclinical stages and help one decide whether to conduct
clinical studies with a drug when F in experimental animals
has been found to be low.
Furthermore, this method of prediction may be used in the
dose escalation in the clinical studies. The dose escalation is
often performed with reference to the AUC or Css which
produces the desired pharmacological effect and is predicted
from preclinical studies using animals and/or in vitro metab-
olism studies. In the case where AUC and Css change in a
nonlinear manner as the dose increases, it is difficult to find
the appropriate dose for the pharmacological effect and much
more care is required when carrying out dose escalation
studies. Even when nonlinear metabolism is observed, our
study suggests that the quantitative prediction of in vivo
pharmacokinetics after oral administration of a drug based
on the parameters obtained from in vitro metabolism studies
is possible (fig. 5). Such prediction of pharmacokinetic pa-
rameters under nonlinear conditions will make it possible to
increase the dose more safely and efficiently to obtain the
desired pharmacological effect.
In conclusion, the predictability of the AUCoral and F of
YM796 from in vitro data was good for all species suggesting
that, even when nonlinear metabolism is observed, quanti-
tative prediction of in vivo pharmacokinetics after oral ad-
ministration of a drug is possible using the parameters ob-
tained from in vitro metabolism studies, taking into
consideration the rate of drug absorption into the portal vein.
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